Skip to content

Trial Summary

Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Acronym:

R2810-ONC-1540

ACTRN/NCT /ethics:

NCT02760498

Scientific title:

A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Sponsor / Cooperative group:

Regeneron

Trial & Patient Characteristics

Cancer TypeMelanoma & other skin
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
SexBoth
Tumour Stream Cutaneous squamous cell carcinoma
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date-
Anticipated End Date-

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Brian Stein
Recruitment StatusRecruiting